Advertisement
JNJ vs LLY
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- Divergent growth profiles: LLY is a high-growth leader driven by GLP-1 (glucagon-like peptide-1) obesity and diabetes treatments, while JNJ is a diversified, lower-beta healthcare compounder.
- Relative performance gap: Both stocks have delivered strong trailing returns, but LLY carries stronger recent momentum and a higher valuation, whereas JNJ offers a more defensive profile and a higher dividend yield.
- Contrasting catalysts: JNJ's recent quarter beat expectations yet the stock fell on slower medical-technology (MedTech) growth and talc litigation costs, while LLY approaches earnings with rising price targets tied to its weight-loss franchise.
- Risk composition differs: JNJ faces legal and MedTech headwinds and biosimilar competition; LLY faces pricing pressure, high expectations, and competitive risk in the obesity market.
- For more detail on key developments and intraday action, explore JNJ Major News and JNJ Today's Price Move, as well as LLY Major News and LLY Today's Price Move.
- To see how automated systems are positioning across this pair and thousands of other tickers, explore Trending AI Robots.
Introduction
Johnson & Johnson and Eli Lilly are two of the largest and most closely watched names in U.S. healthcare, yet they represent almost opposite investment profiles. JNJ is a diversified giant spanning pharmaceuticals and medical devices, prized for stability, cash generation, and dividends. LLY is a growth engine whose GLP-1 treatments for diabetes and obesity have driven exceptional revenue expansion and a market capitalization above $1 trillion. This stock comparison is relevant for traders weighing momentum and catalysts against defensive positioning, and for investors deciding how growth and value-oriented healthcare exposure fit their portfolios.
JNJ Overview and Recent Performance
Johnson & Johnson operates through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). In recent market activity, the company reported quarterly revenue of roughly $25.4 billion, up about 5.9% year over year, with adjusted earnings per share (EPS) of $2.59, above consensus. Pharmaceutical sales grew about 7.7%, led by immunology and oncology products, helping offset declines from biosimilar competition. However, MedTech growth slowed to about 2.5%, pressured by Middle East disruption, European budget constraints, and China pricing. A large talc-related litigation charge and plans to separate the orthopedics unit, DePuy Synthes, also shaped sentiment, and the stock declined following results despite raised full-year guidance. JNJ's lower beta (a measure of volatility relative to the market) and dividend yield reflect its defensive character.
LLY Overview and Recent Performance
Eli Lilly is a pharmaceutical company whose growth has been concentrated in incretin-based therapies for diabetes and obesity, including Mounjaro, Zepbound, and the newer oral treatment Foundayo, with the investigational agent Retatrutide in late-stage development. The company's recent momentum has been strong: shares have climbed toward record levels in recent weeks, and analysts have raised price targets heading into its next earnings report, citing demand across the weight-loss franchise. Revenue and net income grew sharply in the prior fiscal year, and the company continues to invest in manufacturing capacity. At the same time, LLY trades at a materially higher valuation multiple and carries pricing-related and competitive risks, with realized prices facing downward pressure even as volumes expand.
Trending AI Robots
Tickeron maintains a library of hundreds of AI trading bots that collectively trade thousands of different tickers. Because not every automated strategy fits every market regime, Tickeron curates only the most suitable, best-performing bots into the Trending AI Robots section. The bots vary widely in trading style, strategy, timeframe, historical performance, and the sets of tickers they monitor, which can include names such as JNJ and LLY alongside the broader market. This diversity lets traders review systems whose risk profiles and holding periods align with their own approach. Exploring the Trending AI Robots page is a practical way to see which automated strategies are currently favored by the platform's ranking methodology.
Head-to-Head Comparison
The two companies diverge across several dimensions. Business model: JNJ spans pharmaceuticals and medical devices, smoothing risk across end markets, while LLY is more concentrated in a high-growth therapeutic area. Growth drivers: JNJ leans on a broad pipeline and new product launches to offset patent expiries, whereas LLY's trajectory hinges heavily on GLP-1 volume growth and next-generation obesity candidates. Momentum and sentiment: LLY has exhibited stronger recent price momentum and analyst enthusiasm, while JNJ's relative performance has been more measured and its recent earnings reaction negative. Risk factors: JNJ faces litigation, biosimilar erosion, and MedTech softness; LLY faces valuation sensitivity, pricing negotiations, and intense competition. Market positioning: JNJ appeals to income- and stability-oriented investors, while LLY attracts growth-oriented capital comfortable with higher multiples and execution risk.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst strength, and relative positioning, Tickeron's AI would likely lean toward LLY at present. The stock's sustained upward trend, expanding franchise, and rising analyst targets suggest more favorable momentum and catalyst alignment than JNJ, whose recent results were overshadowed by MedTech deceleration and legal charges. That said, LLY's higher valuation and reliance on a concentrated growth story introduce greater downside sensitivity. The preference is probabilistic rather than absolute, reflecting momentum and positioning rather than a judgment on long-term fundamentals or personal suitability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and LLY is a Buy.
JNJ in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
LLY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LLY turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 55 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 216 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for LLY moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 23 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where LLY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
JNJ | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 4 | |
SMR RATING 1..100 | 37 | 14 | |
PRICE GROWTH RATING 1..100 | 19 | 7 | |
P/E GROWTH RATING 1..100 | 7 | 48 | |
SEASONALITY SCORE 1..100 | 50 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (75) in the Pharmaceuticals Major industry is in the same range as LLY (86). This means that JNJ’s stock grew similarly to LLY’s over the last 12 months.
JNJ's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as LLY (4). This means that JNJ’s stock grew similarly to LLY’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that LLY’s stock grew similarly to JNJ’s over the last 12 months.
LLY's Price Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as JNJ (19). This means that LLY’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (48). This means that JNJ’s stock grew somewhat faster than LLY’s over the last 12 months.
| JNJ | LLY | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 59% | 4 days ago 68% |
| Stochastic ODDS (%) | 4 days ago 52% | 4 days ago 63% |
| Momentum ODDS (%) | 4 days ago 45% | 4 days ago 68% |
| MACD ODDS (%) | 4 days ago 40% | 4 days ago 82% |
| TrendWeek ODDS (%) | 4 days ago 47% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 50% | 4 days ago 69% |
| Advances ODDS (%) | 12 days ago 46% | 11 days ago 70% |
| Declines ODDS (%) | 7 days ago 43% | 4 days ago 54% |
| BollingerBands ODDS (%) | 4 days ago 41% | 4 days ago 53% |
| Aroon ODDS (%) | 4 days ago 44% | 4 days ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while LLY’s FA Score has 3 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- LLY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s).
- JNJ’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 6 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +1.11% price change this week, while LLY (@Pharmaceuticals: Major) price change was -4.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.88%. For the same industry, the average monthly price growth was +1.80%, and the average quarterly price growth was +5.50%.
Reported Earning Dates
JNJ is expected to report earnings on Jan 26, 2027.
LLY is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.88% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To JNJ | 1D Price Change % | ||
|---|---|---|---|---|
| JNJ | 100% | +1.43% | ||
| GSK - JNJ | 53% Loosely correlated | -0.16% | ||
| ABBV - JNJ | 53% Loosely correlated | +1.07% | ||
| NVS - JNJ | 52% Loosely correlated | +0.38% | ||
| MRK - JNJ | 48% Loosely correlated | -0.14% | ||
| AMGN - JNJ | 47% Loosely correlated | +0.03% | ||
More | ||||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.